Management of Venous Thromboembolism

Recent Advances in Oral Anticoagulation Therapy

Shannon W. Finks, Toby C. Trujillo, Paul P Dobesh

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Objective: To review clinical data on direct oral anticoagulants (DOACs) used in the acute treatment of venous thromboembolism (VTE) as well as practical considerations when using these products. Data Sources: Searches of PubMed and Google Scholar for VTE, deep vein thrombosis, pulmonary embolism, and relevant drug international nonproprietary names were conducted. Additional online searches were conducted for prescribing information. Study Selection and Data Extraction: Relevant articles on dabigatran, rivaroxaban, apixaban, and edoxaban for the management of VTE compared with oral vitamin K antagonists (VKAs; published between 1966 and December 2015) were reviewed and summarized, together with information on dosing, pharmacokinetics/pharmacodynamics, and drug-drug interactions. Data Synthesis: The DOACs have the potential to circumvent many of the disadvantages of VKAs. At a minimum, they greatly increase the available therapeutic options, thus providing a greater opportunity for clinicians to select a management option that best fits the needs of individual patients. Despite the significant advance that DOACs represent, they are not without risk and require careful consideration of a number of clinical issues to optimize safety and efficacy. Conclusions: The emergence of DOACs for the management of thromboembolic disorders represents a paradigm shift from oral VKAs. The DOACs provide similar efficacy and improved safety in selected patients as compared with VKAs. Clinicians treating VTE need to be familiar with the intricacies involved in using these agents, including the appropriate dose selection for the relevant indication, avoidance of drug-drug and drug-disease interactions, and consideration of dose adjustments in specific clinical situations, such as organ dysfunction.

Original languageEnglish (US)
Pages (from-to)486-501
Number of pages16
JournalAnnals of Pharmacotherapy
Volume50
Issue number6
DOIs
StatePublished - Jan 1 2016

Fingerprint

Venous Thromboembolism
Anticoagulants
Drug Interactions
Pharmaceutical Preparations
Generic Drugs
Therapeutics
Safety
Vitamin K
Information Storage and Retrieval
Pulmonary Embolism
PubMed
Venous Thrombosis
Names
Pharmacokinetics

Keywords

  • apixaban
  • dabigatran
  • deep vein thrombosis
  • direct oral anticoagulants
  • edoxaban
  • pulmonary embolism
  • rivaroxaban
  • target-specific oral anticoagulants
  • venous thromboembolism

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Management of Venous Thromboembolism : Recent Advances in Oral Anticoagulation Therapy. / Finks, Shannon W.; Trujillo, Toby C.; Dobesh, Paul P.

In: Annals of Pharmacotherapy, Vol. 50, No. 6, 01.01.2016, p. 486-501.

Research output: Contribution to journalReview article

@article{7dadacf668ae4d13ab1bd023939293f8,
title = "Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy",
abstract = "Objective: To review clinical data on direct oral anticoagulants (DOACs) used in the acute treatment of venous thromboembolism (VTE) as well as practical considerations when using these products. Data Sources: Searches of PubMed and Google Scholar for VTE, deep vein thrombosis, pulmonary embolism, and relevant drug international nonproprietary names were conducted. Additional online searches were conducted for prescribing information. Study Selection and Data Extraction: Relevant articles on dabigatran, rivaroxaban, apixaban, and edoxaban for the management of VTE compared with oral vitamin K antagonists (VKAs; published between 1966 and December 2015) were reviewed and summarized, together with information on dosing, pharmacokinetics/pharmacodynamics, and drug-drug interactions. Data Synthesis: The DOACs have the potential to circumvent many of the disadvantages of VKAs. At a minimum, they greatly increase the available therapeutic options, thus providing a greater opportunity for clinicians to select a management option that best fits the needs of individual patients. Despite the significant advance that DOACs represent, they are not without risk and require careful consideration of a number of clinical issues to optimize safety and efficacy. Conclusions: The emergence of DOACs for the management of thromboembolic disorders represents a paradigm shift from oral VKAs. The DOACs provide similar efficacy and improved safety in selected patients as compared with VKAs. Clinicians treating VTE need to be familiar with the intricacies involved in using these agents, including the appropriate dose selection for the relevant indication, avoidance of drug-drug and drug-disease interactions, and consideration of dose adjustments in specific clinical situations, such as organ dysfunction.",
keywords = "apixaban, dabigatran, deep vein thrombosis, direct oral anticoagulants, edoxaban, pulmonary embolism, rivaroxaban, target-specific oral anticoagulants, venous thromboembolism",
author = "Finks, {Shannon W.} and Trujillo, {Toby C.} and Dobesh, {Paul P}",
year = "2016",
month = "1",
day = "1",
doi = "10.1177/1060028016632785",
language = "English (US)",
volume = "50",
pages = "486--501",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "6",

}

TY - JOUR

T1 - Management of Venous Thromboembolism

T2 - Recent Advances in Oral Anticoagulation Therapy

AU - Finks, Shannon W.

AU - Trujillo, Toby C.

AU - Dobesh, Paul P

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objective: To review clinical data on direct oral anticoagulants (DOACs) used in the acute treatment of venous thromboembolism (VTE) as well as practical considerations when using these products. Data Sources: Searches of PubMed and Google Scholar for VTE, deep vein thrombosis, pulmonary embolism, and relevant drug international nonproprietary names were conducted. Additional online searches were conducted for prescribing information. Study Selection and Data Extraction: Relevant articles on dabigatran, rivaroxaban, apixaban, and edoxaban for the management of VTE compared with oral vitamin K antagonists (VKAs; published between 1966 and December 2015) were reviewed and summarized, together with information on dosing, pharmacokinetics/pharmacodynamics, and drug-drug interactions. Data Synthesis: The DOACs have the potential to circumvent many of the disadvantages of VKAs. At a minimum, they greatly increase the available therapeutic options, thus providing a greater opportunity for clinicians to select a management option that best fits the needs of individual patients. Despite the significant advance that DOACs represent, they are not without risk and require careful consideration of a number of clinical issues to optimize safety and efficacy. Conclusions: The emergence of DOACs for the management of thromboembolic disorders represents a paradigm shift from oral VKAs. The DOACs provide similar efficacy and improved safety in selected patients as compared with VKAs. Clinicians treating VTE need to be familiar with the intricacies involved in using these agents, including the appropriate dose selection for the relevant indication, avoidance of drug-drug and drug-disease interactions, and consideration of dose adjustments in specific clinical situations, such as organ dysfunction.

AB - Objective: To review clinical data on direct oral anticoagulants (DOACs) used in the acute treatment of venous thromboembolism (VTE) as well as practical considerations when using these products. Data Sources: Searches of PubMed and Google Scholar for VTE, deep vein thrombosis, pulmonary embolism, and relevant drug international nonproprietary names were conducted. Additional online searches were conducted for prescribing information. Study Selection and Data Extraction: Relevant articles on dabigatran, rivaroxaban, apixaban, and edoxaban for the management of VTE compared with oral vitamin K antagonists (VKAs; published between 1966 and December 2015) were reviewed and summarized, together with information on dosing, pharmacokinetics/pharmacodynamics, and drug-drug interactions. Data Synthesis: The DOACs have the potential to circumvent many of the disadvantages of VKAs. At a minimum, they greatly increase the available therapeutic options, thus providing a greater opportunity for clinicians to select a management option that best fits the needs of individual patients. Despite the significant advance that DOACs represent, they are not without risk and require careful consideration of a number of clinical issues to optimize safety and efficacy. Conclusions: The emergence of DOACs for the management of thromboembolic disorders represents a paradigm shift from oral VKAs. The DOACs provide similar efficacy and improved safety in selected patients as compared with VKAs. Clinicians treating VTE need to be familiar with the intricacies involved in using these agents, including the appropriate dose selection for the relevant indication, avoidance of drug-drug and drug-disease interactions, and consideration of dose adjustments in specific clinical situations, such as organ dysfunction.

KW - apixaban

KW - dabigatran

KW - deep vein thrombosis

KW - direct oral anticoagulants

KW - edoxaban

KW - pulmonary embolism

KW - rivaroxaban

KW - target-specific oral anticoagulants

KW - venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84966783522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966783522&partnerID=8YFLogxK

U2 - 10.1177/1060028016632785

DO - 10.1177/1060028016632785

M3 - Review article

VL - 50

SP - 486

EP - 501

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 6

ER -